(NewsDirect)
Patrys Ltd (ASX:PAB) managing director and CEO Dr James Campbelltalks with Proactive’s Elisha Newell about two new patents thatadvance protection for the company’s antibody technology through to2039. The first patent, co-filed with Yale University, is the first USpatent to be granted specifically for PAT-DX1 and PAT-DX3, while thesecond covers deoxymabs with nanocarriers — a combination that couldprovide a powerful new approach for treating cancer. Dr Campbellhighlights the growing opportunity in the cancer therapeutics spaceand says Patrys looks forward to its first-in-human clinical trial forPAT-DX1 next year.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.